PAP
APGE icon

Persistent Asset Partners’s Apogee Therapeutics APGE Stock Holding History

Persistent Asset Partners’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.93M Hold
566
– – 0.72% 32
2025
Q4 		$1.64M Buy
566
+271
+92% +$17.1K 0.74% 28
2025
Q3 		$28.7K Sell
295
-67
-19% -$2.56K 0.02% 197
2025
Q2 		$378K Buy
362
+69
+24% +$2.63K 0.28% 91
2025
Q1 		$233K Buy
293
+239
+443% +$9.24K 0.2% 91
2024
Q4 		$54.5K Buy
+54
New +$2.75K 0.05% 115

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Persistent Asset Partners's APGE Position: Q1 2026 in Review

Persistent Asset Partners sold out of Apogee Therapeutics (APGE) in Q1 2026, closing a stake of 2,445 shares — an estimated $178K sold.

Persistent Asset Partners first reported a position in APGE in Q4 2024 and held it in 5 quarters. The position peaked at $742K in Q4 2024. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • Persistent Asset Partners reported no remaining Apogee Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 2,445 Apogee Therapeutics shares in Q1 2026, an estimated $178K.
  • Persistent Asset Partners first reported a position in Apogee Therapeutics in Q4 2024 and held it in 5 quarters.
  • Persistent Asset Partners's Apogee Therapeutics position peaked at $742K in Q4 2024.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.